Q-omics provides the consensus-scored FAM222B profile across patient tissues and cancer cell-line models. FAM222B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FAM222B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, FAM222B RNA expression shows 20,895 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where FAM222B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM222B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM222B survival associations across molecular data types. FAM222B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM222B RNA expression–survival associations across cancer types. High FAM222B expression shows unfavorable associations in MESO, LIHC, SKCM, KICH and CESC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FAM222B RNA expression.
This table summarizes FAM222B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM222B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM222B shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, LUAD, BRCA and KIRP. The HNSC box plot shows higher FAM222B RNA expression in tumor versus normal tissue (log2 FC = +0.555, t-test p < 0.001).
This table shows molecular features associated with FAM222B in patient tissues and cancer cell lines. In patient samples, FAM222B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM222B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
